GlassScriptPhysician profile
Jennifer E Bramel
NPI 1972266328
$2,920.76
in general payments reported to CMS, 2019-2025
35 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,046 · 2023: $802 · 2024: $879 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.24 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $235.92 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $228.36 | 2022-2023 | Xpovio |
| Lilly USA, LLC | $223.74 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Tempus Ai, INC | $203.25 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $166.89 | 2023-2024 | Jakafi, Monjuvi |
| Pfizer INC. | $157.50 | 2022-2024 | |
| Genentech, INC. | $145.75 | 2024 | |
| Amgen INC. | $138.90 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Immunogen, INC. | $129.32 | 2023 | Elahere |
| Merck Sharp & Dohme LLC | $111.83 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $102.02 | 2022-2024 | Padcev |
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Puma Biotechnology, INC. | $83.95 | 2022-2023 | |
| Celgene Corporation | $80.33 | 2022-2025 | Reblozyl |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66.98 | 2022-2023 | |
| Seagen INC. | $48.56 | 2022 | |
| Janssen Biotech, INC. | $45.29 | 2022-2024 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $40.17 | 2022 | |
| Stemline Therapeutics INC. | $35.56 | 2022-2023 | Orserdu |
| Aveo Pharmaceuticals, INC. | $35.33 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $33.21 | 2023 | Imbruvica |
| Apellis Pharmaceuticals, INC. | $30.39 | 2022 | |
| Sobi, INC | $29.75 | 2022 | |
| Gilead Sciences, INC. | $29.42 | 2023 | |
| Eisai INC. | $24.36 | 2024 | |
| Daiichi Sankyo INC. | $23.13 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.84 | 2023 | |
| Glaxosmithkline, LLC. | $22.42 | 2024 | Ojjaara |
| Pharming Healthcare, INC. | $19.70 | 2022 | |
| Tactile Systems Technology INC | $19.19 | 2022 | |
| Chiesi USA, INC. | $18.76 | 2022 | |
| Tolmar, INC. | $15.66 | 2024 | |
| Global Blood Therapeutics, INC. | $15.51 | 2022 | |
| Adaptive Biotechnologies Corporation | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bramel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.